Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
The purpose of this trial is to determine

1. Disease stabilization/response rate after six 21-day cycles of ibrutinib
2. Remission status after six, twelve and 20 21-day cycles of ibrutinib
Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
DRUG: Ibrutinib
Response Rate, after 6 cycles (each cycle is 21 days) of Ibrutinib
Remission status, Remission status after six, twelve and 20 21-day cycles of ibrutinib
The purpose of this trial is to determine

1. Disease stabilization/response rate after six 21-day cycles of ibrutinib
2. Remission status after six, twelve and 20 21-day cycles of ibrutinib